Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population
Conclusion: Our findings revealed that the Sinopharm and Oxford-AstraZeneca vaccines are effective in the production of neutralizing antibodies in healthy subjects and patients with autoimmune disorders undergoing immunosuppressive therapies without considerable reactogenicity.PMID:38494849 | PMC:PMC10946076 | DOI:10.1177/03946320241239202 (Source: International Journal of Immunopathology and Pharmacology)
Source: International Journal of Immunopathology and Pharmacology - March 18, 2024 Category: Allergy & Immunology Authors: Amin Moradi Hasan-Abad Mohsen Arbabi Hamidreza Gilasi Hossein Motedayyen Source Type: research
Lichen planus triggered by COVID-19 vaccination: A case series
We present a case series of lichen planus that appeared after receiving the COVISHIELD vaccine from Oxford-AstraZeneca. In order to rule out any further potential triggers, like recent infections, prior drug use, smoking, dental treatments, etc., a thorough history was collected in each instance. Skin biopsies were used to confirm each case's diagnosis. In nearly all of the cases, skin biopsies revealed typical dermatopathological features of lichen planus.PMID:38482327 | PMC:PMC10931865 | DOI:10.4103/jfmpc.jfmpc_664_23 (Source: Primary Care)
Source: Primary Care - March 14, 2024 Category: Primary Care Authors: Murali Narasimhan Ramachandran Ramakrishnan Divya Sree Varri Muthubharathi Sivasubramanian Source Type: research
Long-term analysis of humoral responses and spike-specific T cell memory to Omicron variants after different COVID-19 vaccine regimens
ConclusionReduction of humoral and CD4+ T cell responses against Omicron variants in vaccinees suggested that vaccine effectiveness after eight months may not have sufficient protection against the new emerging variants, which provides valuable information for future vaccination strategies such as receiving BA.4/5 or XBB.1-based bivalent vaccines. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - March 12, 2024 Category: Allergy & Immunology Source Type: research
Sporadic Kaposi Sarcoma Following a COVID-19 Vaccine: Mere Coincidence or Something More?
Cureus. 2024 Feb 9;16(2):e53925. doi: 10.7759/cureus.53925. eCollection 2024 Feb.ABSTRACTIn this case report, we present a distinctive occurrence of classic Kaposi sarcoma (KS) in an individual of Latin origin, emerging seven days following the administration of the third dose of the ChAdOx1 nCoV-19 (AstraZeneca) vaccine. The progression of KS continued over two months, culminating in the development of a tumor. Given the absence of prior reports on KS development post-COVID-19 vaccination, the primary aim of this report is to explore the potential relationship between the ChAdOx1 nCoV-19 vaccine, reactivation of Kaposi sa...
Source: Herpes - March 11, 2024 Category: Infectious Diseases Authors: Jes ús Iván Martínez-Ortega Arely Gissell Ramirez Cibrian Elvis Martinez-Jaramillo Maria Del Consuelo Garc ía Silva Source Type: research
Augmenting DMTA using predictive AI modelling at AstraZeneca
Drug Discov Today. 2024 Mar 7:103945. doi: 10.1016/j.drudis.2024.103945. Online ahead of print.ABSTRACTDesign-Make-Test-Analyse (DMTA) is the discovery cycle through which molecules are designed, synthesised, and assayed to produce data that in turn are analysed to inform the next iteration. The process is repeated until viable drug candidates are identified, often requiring many cycles before reaching a sweet spot. The advent of artificial intelligence (AI) and cloud computing presents an opportunity to innovate drug discovery to reduce the number of cycles needed to yield a candidate. Here, we present the Predictive Insi...
Source: Drug Discovery Today - March 9, 2024 Category: Drugs & Pharmacology Authors: Gian Marco Emma Evertsson David J Riley Christian Tyrchan Prakash Chandra Rathi Source Type: research
Augmenting DMTA using predictive AI modelling at AstraZeneca
Drug Discov Today. 2024 Mar 7:103945. doi: 10.1016/j.drudis.2024.103945. Online ahead of print.ABSTRACTDesign-Make-Test-Analyse (DMTA) is the discovery cycle through which molecules are designed, synthesised, and assayed to produce data that in turn are analysed to inform the next iteration. The process is repeated until viable drug candidates are identified, often requiring many cycles before reaching a sweet spot. The advent of artificial intelligence (AI) and cloud computing presents an opportunity to innovate drug discovery to reduce the number of cycles needed to yield a candidate. Here, we present the Predictive Insi...
Source: Drug Discovery Today - March 9, 2024 Category: Drugs & Pharmacology Authors: Gian Marco Emma Evertsson David J Riley Christian Tyrchan Prakash Chandra Rathi Source Type: research
Augmenting DMTA using predictive AI modelling at AstraZeneca
Drug Discov Today. 2024 Mar 7:103945. doi: 10.1016/j.drudis.2024.103945. Online ahead of print.ABSTRACTDesign-Make-Test-Analyse (DMTA) is the discovery cycle through which molecules are designed, synthesised, and assayed to produce data that in turn are analysed to inform the next iteration. The process is repeated until viable drug candidates are identified, often requiring many cycles before reaching a sweet spot. The advent of artificial intelligence (AI) and cloud computing presents an opportunity to innovate drug discovery to reduce the number of cycles needed to yield a candidate. Here, we present the Predictive Insi...
Source: Drug Discovery Today - March 9, 2024 Category: Drugs & Pharmacology Authors: Gian Marco Emma Evertsson David J Riley Christian Tyrchan Prakash Chandra Rathi Source Type: research
Augmenting DMTA using predictive AI modelling at AstraZeneca
Drug Discov Today. 2024 Mar 7:103945. doi: 10.1016/j.drudis.2024.103945. Online ahead of print.ABSTRACTDesign-Make-Test-Analyse (DMTA) is the discovery cycle through which molecules are designed, synthesised, and assayed to produce data that in turn are analysed to inform the next iteration. The process is repeated until viable drug candidates are identified, often requiring many cycles before reaching a sweet spot. The advent of artificial intelligence (AI) and cloud computing presents an opportunity to innovate drug discovery to reduce the number of cycles needed to yield a candidate. Here, we present the Predictive Insi...
Source: Drug Discovery Today - March 9, 2024 Category: Drugs & Pharmacology Authors: Gian Marco Emma Evertsson David J Riley Christian Tyrchan Prakash Chandra Rathi Source Type: research
Augmenting DMTA using predictive AI modelling at AstraZeneca
Drug Discov Today. 2024 Mar 7:103945. doi: 10.1016/j.drudis.2024.103945. Online ahead of print.ABSTRACTDesign-Make-Test-Analyse (DMTA) is the discovery cycle through which molecules are designed, synthesised, and assayed to produce data that in turn are analysed to inform the next iteration. The process is repeated until viable drug candidates are identified, often requiring many cycles before reaching a sweet spot. The advent of artificial intelligence (AI) and cloud computing presents an opportunity to innovate drug discovery to reduce the number of cycles needed to yield a candidate. Here, we present the Predictive Insi...
Source: Drug Discovery Today - March 9, 2024 Category: Drugs & Pharmacology Authors: Gian Marco Emma Evertsson David J Riley Christian Tyrchan Prakash Chandra Rathi Source Type: research
Augmenting DMTA using predictive AI modelling at AstraZeneca
Drug Discov Today. 2024 Mar 8:103945. doi: 10.1016/j.drudis.2024.103945. Online ahead of print.ABSTRACTDesign-Make-Test-Analyse (DMTA) is the discovery cycle through which molecules are designed, synthesised, and assayed to produce data that in turn are analysed to inform the next iteration. The process is repeated until viable drug candidates are identified, often requiring many cycles before reaching a sweet spot. The advent of artificial intelligence (AI) and cloud computing presents an opportunity to innovate drug discovery to reduce the number of cycles needed to yield a candidate. Here, we present the Predictive Insi...
Source: Drug Discovery Today - March 9, 2024 Category: Drugs & Pharmacology Authors: Gian Marco Emma Evertsson David J Riley Christian Tyrchan Prakash Chandra Rathi Source Type: research
Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments
We read Kennedy et al1’s findings with interest, and report in-depth analyses of antibody and T cell responses in patients with inflammatory bowel disease (IBD) to COVID-19 vaccination. We prospectively recruited 100 SARS-CoV-2-uninfected patients with IBD on varying treatments at the Royal Melbourne Hospital (HREC/74403/MH-2021). Healthcare workers who did not have IBD and were not on immunosuppressive medication were enrolled as controls with approvals from Melbourne Health (HREC/68355/MH-2020) and University of Melbourne (HREC 22268, 21626). Participant characteristics are outlined in table 1. IBD medication regim...
Source: Gut - March 7, 2024 Category: Gastroenterology Authors: Zhang, E., Nguyen, T. H. O., Allen, L. F., Kedzierski, L., Rowntree, L. C., Chang, S. Y., Zhang, W., Habel, J. R., Foo, I. J., Menon, T., Mitchell, J., Leong, R. W., Bond, K., Williamson, D. A., Kedzierska, K., Christensen, B. Tags: Gut, COVID-19 PostScript Source Type: research
